Postbiotics, Inc. and Sabinsa Corporation, announced today a multinational distribution agreement including the USA, Canada, European Union, and other significant markets (including India and Japan) for the dietary supplement and functional food ingredient PoZibio^® for age-related digestive health conditions including Leaky Gut Syndrome (LGS).

PoZibio^®, the next generation of digestive health^®, is a patent-protected postbiotic composition of Lipoteichoic Acid, isolated from the cell walls of a heat-treated strain of Lactobacillus paracasei (Patent Number US 11,622,981 B2). Discovered by gut microbiome longevity researchers at the Wake Forest University College of Medicine, the ingredient is suitable for use in functional foods, medical foods, and dietary supplements due to its low dose, heat stability, and neutral taste profile.

Leaky Gut Syndrome (LGS) increases with normal aging and environmental conditions, and is associated with occasional symptoms of irregularity, diarrhea, gas, bloating, fatigue, age-related decline in cognition, metabolism and muscle health, decreased immunity, and decreased GLP-1 production (a peptide linked to satiety and blood glucose regulation).

Shaheen Majeed, Global CEO & Managing Director of Sami-Sabinsa Group, stated “I’m pleased to bring forth an ingredient for a condition that is very under addressed in the marketplace. Additionally, this marks one of the very first partnerships Sabinsa enters into globally, and at its core represents the best of science and functionality.”

Doug Lynch, Co-founding Partner and Chief Commercial Officer of Postbiotics, Inc. stated “We are pleased to be working with Sabinsa, and believe their global sales organization and manufacturing prowess are perfect complements to our world-class research. This distribution partnership with Sabinsa for will ensure consumer brands of supplements and foods in the United States and beyond will experience the many benefits from postbiotics on improving health and lifespan.”

Hariom Yadav, PhD., Associate Professor of Neurosurgery and Brain Repair and Director of University of South Florida’s Center for Microbiome Research, who discovered PoZibio^® while at Wake Forest, stated that “The gut-brain axis benefits we have shown from PoZibio^® are compelling. PoZibio^® has been shown to increase the mucous layer of the gut wall, inhibit age-related inflammation (inflammaging), support cognitive function, and promote muscle and metabolic health, in prior and ongoing research.”

Generally Regarded as Safe (GRAS), non-GMO PoZibio^® is available for sale today, as a proprietary postbiotic ingredient, to makers of high-quality dietary supplement and functional foods.

Note: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.